Trials / Completed
CompletedNCT00090116
The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease
A Randomized, Double-Blind,Placebo-Controlled Evaluation of the Safety and Efficacy of Neramexane Monotherapy in Patients With Moderate to Severe Dementia of the Alzheimer's Type
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (planned)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate. Glutamate helps transmit messages between nerve cells through interaction with a certain type of receptor (N-methyl-D-aspartate, NMDA) on the cell. Neramexane is a new drug that blocks the effects of excessive glutamate at the receptor (NMDA receptor antagonist).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Neramexane |
Timeline
- Start date
- 2003-03-01
- Primary completion
- 2005-03-01
- Completion
- 2005-03-01
- First posted
- 2004-08-26
- Last updated
- 2012-03-05
Locations
34 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00090116. Inclusion in this directory is not an endorsement.